HLA-F在肝细胞癌中的表达及预后意义  

Expression and prognostic significance of HLA-F in hepatocellular carcinoma

作　　者：徐永富[1] 章文龙[1] 胡鹏[1] 朱昱[1] 方哲平[1] 

机构地区：[1]温州医科大学附属浙江省台州医院肝胆外科,浙江省317000

出　　处：《中华普通外科杂志》2014年第8期630-633,共4页Chinese Journal of General Surgery

基　　金：浙江省医药卫生科技基金资助项目（2009A220,2014KYA227,2014KYB308）;浙江省科学技术厅基金资助项目（2009C33096）

摘　　要：目的 探讨人类白细胞抗原F（human leukocyte antigen F,HLA-F）在肝细胞肝癌组织中的表达特点及其与肝癌患者临床病理因素和预后的关系.方法 采用免疫组织化学方法检测115例肝癌组织及其邻近正常肝癌组织中HLA-F的表达情况,并分析HLA-F表达与各临床病理因素以及患者预后的相关性.结果 HLA-F在肝癌癌灶组织及正常肝脏组织中表达阳性率分别为47.0％ （54/115）及10.6％（7/66）,差异有统计学意义（Х^2=24.799,P＜0.05）;肝癌癌灶组织中HLA-F表达量与门静脉癌栓（Х^2=7.644,P=0.006）、肿瘤数目（Х^2 =4.210,P=0.040）及患者性别（Х^2=6.759,P=0.009）等因素相关.HLA-F表达阳性者术后平均生存时间为34.0个月（95％ CI：27.5 ～40.5个月）明显短于阴性患者44.6个月（95％CI：38.3～ 50.9个月）,差异有统计学意义（Х^2=5.148,P=0.023）.结论 HLA-F表达是肝癌患者的独立预后影响因素.Objective To investigate the expression of human leukocyte antigen F （HLA-F） in hepatocellular carcinoma （HCC） tissues and to evaluate its relation to clinicopathological features and prognosis of HCC.Methods HLA-F expression of tumor lesions and their adjacent normal liver tissues from 115 HCC patients were analyzed by immunohistochemistry,and its relationship between HLA-F expression and the clinicopathological features and prognosis of HCC patients was also analyzed.Results HLA-F expression was positive in 47.0% （54/115） of the HCC lesions and in 10.6% （7/66） of the normal liver tissues （Х^2 =24.799,P 〈 0.05）.HLA-F expression in HCC lesions was significantly correlated with portal vein invasions （Х^2 =7.644,P =0.006）,tumor number （Х^2 =4.210,P =0.040） and patient sex （Х^2 =6.759,P =0.009）.The mean survival time of the HLA-F positive HCC patients was 34.0 months（95% CI：27.5-40.5 months）,which was significantly shorter than that of HLA-F negative HCC patients（44.6 months,95% CI：38.3-50.9months） （Х^2 =5.148,P =0.023）.HLA-F expression was an independent predictor of overall survival of HCC patients.Conclusions Positive HLA-F expression is negatively correlated with the prognosis of HCC patients.

关 键 词：癌 肝细胞 HLA抗原 存活率分析 

分 类 号：R735.7[医药卫生—肿瘤]